A comparative study of interaction of tetracycline with several proteins using time resolved anisotropy, phosphorescence, docking and FRET

A comparative study of the interaction of an antibiotic Tetracycline hydrochloride (TC) with two albumins, Human serum albumin (HSA) and Bovine serum albumin (BSA) along with Escherichia Coli Alkaline Phosphatase (AP) has been presented exploiting the enhanced emission and anisotropy of the bound drug. The association constant at 298 K is found to be two orders of magnitude lower in BSA/HSA compared to that in AP with number of binding site being one in each case. Fluorescence resonance energy transfer (FRET) and molecular docking studies have been employed for the systems containing HSA and BSA to find out the particular tryptophan (Trp) residue and the other residues in the proteins involved in the binding process. Rotational correlation time (θc) of the bound TC obtained from time resolved anisotropy of TC in all the protein-TC complexes has been compared to understand the binding mechanism. Low temperature (77 K) phosphorescence (LTP) spectra of Trp residues in the free proteins (HSA/BSA) and in the complexes of HSA/BSA have been used to specify the role of Trp residues in FRET and in the binding process. The results have been compared with those obtained for the complex of AP with TC. The photophysical behaviour (viz., emission maximum, quantum yield, lifetime and θc) of TC in various protic and aprotic polar solvents has been determined to address the nature of the microenvironment of TC in the protein-drug complexes

Energy transfer photophysics from serum albumins to sequestered 3-hydroxy-2-naphthoic acid, an excited state intramolecular proton-transfer probe

The steady-state and time-resolved studies of the sensitized emission of the excited-state proton transfer (ESIPT) probe 3-hydroxy-2-naphthoic acid (3HNA) when bound to bovine serum albumin (BSA) and human serum albumin (HSA) indicate that the nonradiative dipole−dipole Förster type energy transfer from Trp singlet state of proteins to the ESIPT singlet state of 3HNA is greater in the case of HSA. This is supported by the distance and the orientation of the donor−acceptor pair obtained from the protein−ligand docking studies. The docking studies of the complex of BSA−3HNA also indicate that Trp 134 rather than Trp 213 is involved in the energy transfer process. The local environment of Trp 134 in BSA rather than that of Trp 213 is perturbed because of interaction with 3HNA as revealed by the optical resolution of Trp 134 phosphorescence in the complex at 77 K. Docking studies support the larger rotational correlation time, θc (≈ 50 ns), observed for Trp residue/residues in the complexes of HSA and BSA compared with that in the free proteins

Fluorescence, anisotropy and docking studies of proteins through excited state intramolecular proton transfer probe molecules

The enhanced fluorescence and anisotropy of the ESIPT emission of 3-hydroxy-2-naphthoic acid (3HNA) in the complexes of 3HNA with bovine serum albumin (BSA) and human serum albumin (HSA) showed the formation of 1:1 complex [binding constant = 5.3 × 10⁵ M⁻¹ for BSA and = 2.2 × 10⁵ M⁻¹for HSA]. The ESIPT emission of the probe in non-polar, polar protic, polar aprotic and mixed solvents indicate that the position and the quantum yield of the emission are governed by the intermolecular hydrogen bonding ability and the polarity/polarizability of the solvents. Rotational correlation time of 3HNA (2.4 ns and 5.2 ns in BSA and HSA, respectively) obtained from the time resolved anisotropy decay of the ESIPT emission suggests motional restriction of the probe. Docking studies reveal H-bonding of some residues with the probe and loss of accessible surface area of several residues located near binding site

Characterization of the tryptophan residues of human placental ribonuclease inhibitor and its complex with bovine pancreatic ribonuclease A by steady-state and time-resolved emission spectroscopy

Human placental ribonuclease inhibitor (hRI) containing six tryptophan (Trp) residues located at positions 19, 261, 263, 318, 375, and 438 and its complex with RNase A have been studied using steady-state and time-resolved fluorescence (298 K) as well as low-temperature phosphorescence (77 K). Two Trp residues in wild-type hRI and also in the protein−protein complex with RNase A are resolved optically. The accessible surface area values of Trp residues in the wild-type hRI and its complex and consideration of inter-Trp energy transfer in the wild-type hRI reveal that one of the Trp residues is Trp19, which is located in a hydrophobic buried region. The other Trp residue is tentatively assigned as Trp375 based on experimental results on wild-type hRI and its complex. This residue in the wild-type hRI is more or less solvent exposed. Both the Trp residues are perturbed slightly on complex formation. Trp19 moves slightly toward a more hydrophobic region, and the environment of Trp375 becomes less solvent exposed. The complex formation also results in a more heterogeneous environment for both the optically resolved Trp residues

Interaction of serum albumins with fluorescent ligand 4-azido coumarin: spectroscopic analysis and molecular docking studies

Steady state fluorescence and time resolved fluorescence studies at 298 K and low temperature phosphorescence (LTP) studies at 77 K of the interaction of bovine serum albumin (BSA) and human serum albumin (HSA) with ligand 4-azido-2H-chromen-2-one or 4-azidocoumarin (4-AC) have been carried out to visualize the location of the binding site and perturbation of the binding site of the tryptophan (Trp)/tyrosine (Tyr) of the protein(s) by monitoring the emission maxima of Trp residue(s) in proteins. The fluorescence quenching study of Trp estimated that the binding constant for both protein–ligand complexes is in the order of ∼10⁶ with binding site 1. Perturbation in the secondary structures of serum albumins due to binding of 4-AC is also observed from circular dichroism (CD) studies. An energy transfer (ET) study further demonstrated that the non-radiative singlet–singlet ET that takes place from the Trp singlet states of proteins to the singlet state of ligands is greater in the case of BSA. This is supported by the distance and orientation of the donor–acceptor pair obtained from molecular docking studies. The molecular docking studies were also fruitfully exploited to understand the involvement of Trp213 in BSA and Trp214 in HSA in the ET process along with the perturbation of the residues around 5 Å from the ligand 4-AC. Phosphorescence spectra at 77 K of the Trp residues in the free proteins (BSA/HSA) and in the complexes of BSA/HSA have also been utilized to specify the role of Trp residues in ET and the binding process

Interaction of multitryptophan protein with drug: An insight into the binding mechanism and the binding domain by time resolved emission, anisotropy, phosphorescence and docking

The interaction of antibiotic Tetracycline hydrochloride (TC) with Alkaline Phosphatase (AP) from Escherichia coli, an important target enzyme in medicinal chemistry, having tryptophan (Trp) residues at 109, 220 and 268 has been studied using the steady state and time resolved emission of the protein and the enhanced emission of the bound drug. The association constant at 298 K (≈10⁶ [M]⁻¹) and the number of binding site (= 1) were estimated using the quenched Trp emission of AP, the enhanced emission and the anisotropy of the bound drug. The values of ΔH⁰ and ΔS⁰ are indicative of electrostatic and H-bonding interaction. The low temperature phosphorescence of free AP and the protein- drug complex and molecular docking comprehensively prove the specific involvement of partially exposed Trp 220 in the binding process without affecting Trp 109 and Trp 268. The Förster energy transfer (ET) efficiency and the rate constant from the Trp residue to TC = 0.51 and ≈10⁸ s⁻¹ respectively. Arg 199, Glu 219, Trp 220, Lys 223, Ala 231, Arg 232 and Tyr 234 residues are involved in the binding process. The motional restriction of TC imposed by nearby residues is reflected in the observed life time and the rotational correlation time of bound TC

De-Novo drug design of novel 1,2,3–triazole-naphthamide as an inhibitor of SARS-Cov-2 main protease: Synthesis, bioinformatics and biophysical studies

1001-1011A novel 1,2,3-triazole-napthamide molecule (SSAM-1) is designed as per De-Novo drug design method and synthesized by using copper-catalyzed alkyne-azide cycloaddition reaction. The interaction studies of SSAM-1 with bovine serum albumin (BSA), human serum albumin (HSA) and bromelain (BMLN) are investigated by steady state fluorescence spectroscopic studies. The experimental results for these interaction studies are validated by molecular docking method. The theoretical prediction of ADMET properties of SSAM-1 are also performed using computational methods. All these studies indicate significant and spontaneous binding of SSAM-1 with serum albumins and BMLN at pH 7 under varying temperature conditions (288K, 298K, 308K). In all the three cases the interaction of the molecule with the proteins and enzymes led to quenching of the fluorescence emission (mainly via static quenching mechanism) of tryptophan (Trp) residue present in the proteins and in the enzyme. The complexation with SSAM-1 changes the microenvironment of the Trp residue(s) of BSA, HSA and BMLN. Strong binding affinity between proteins and SSAM-1 is indicated by the binding constant values, which is in 103-105 orders. Hydrophobic forces are acting as the major interacting forces for SSAM-1-HSA interaction while H-bonding and van der Waals forces are acting as the primary interacting forces for SSAM-1 interacting with BSA and BMLN. ADMET prediction reveals the drug-able nature of SSAM-1 which is justified due to its ability to bind with the serum albumins. In addition binding study of SSAM-1 with BMLN indicates its possibility of oral administration. Conducting such binding studies of the newly synthesized triazole with biomolecules, an effort is made to assess the contribution of a novel compound to the development of medicines for the drug design process at a very early stage of the research

Steady State and Time Resolved Emission of TC in Various Solvents.

<p>(<b>A</b>) Fluorescence spectra of TC (25 µM) at 298 K in (1) water, (2) ethanol (EtOH), (3) isopropanol (iPrOH), (4) ethylene glycol (EG), (5) dimethylformamide (DMF), (6) dimethyl sulphoxide (DMSO); λ_exc = 370 nm; excitation and emission band pass = 10 nm and 5 nm respectively. (<b>B</b>) Fluorescence decay of TC (25 µM) at 298 K in (B) EtOH, iPr-OH, EG, DMF, DMSO; λexc = 370 nm; excitation and emission bandpass = 10 nm each.</p